Nodal marginal zone lymphoma
Prepared with OnCo (onco.cc/prep/nodal-marginal-zone-lymphoma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
8 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Exclusion immunophenotype: CD20 positive, CD5, CD10, cyclin D1 and BCL6 negative, KMT2D, PTPRD, NOTCH2 and KLF2 mutations, Absence of extranodal or splenic disease on staging), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (all stages), which of the standard options do you recommend and why?
- 6.Am I a candidate for Rituximab, Bendamustine, Lenalidomide or related drugs, and what side effects should I expect?
- 7.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 8.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: Exclusion immunophenotype: CD20 positive, CD5, CD10, cyclin D1 and BCL6 negative, KMT2D, PTPRD, NOTCH2 and KLF2 mutations, Absence of extranodal or splenic disease on staging.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- All stages: Treated as follicular lymphoma of the same stage: radiotherapy when localised, rituximab with or without chemotherapy when advanced, lenalidomide-rituximab or BTK inhibitors on relapse. (Follicular lymphoma, Rituximab, Bendamustine, Lenalidomide, Zanubrutinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.